MIRM vs. BLTE, SYRE, COLL, IRWD, PCRX, GMTX, LGND, VRNA, MNKD, and ABCL
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Belite Bio (BLTE), Spyre Therapeutics (SYRE), Collegium Pharmaceutical (COLL), Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), Verona Pharma (VRNA), MannKind (MNKD), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio (NASDAQ:BLTE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.
0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Belite Bio has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Belite Bio has higher earnings, but lower revenue than Mirum Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Belite Bio has a net margin of 0.00% compared to Belite Bio's net margin of -86.33%. Mirum Pharmaceuticals' return on equity of -54.05% beat Belite Bio's return on equity.
Mirum Pharmaceuticals received 89 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.24% of users gave Belite Bio an outperform vote while only 72.19% of users gave Mirum Pharmaceuticals an outperform vote.
In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Belite Bio. MarketBeat recorded 16 mentions for Mirum Pharmaceuticals and 6 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.51 beat Mirum Pharmaceuticals' score of 0.49 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.
Belite Bio presently has a consensus price target of $44.83, suggesting a potential upside of 5.49%. Mirum Pharmaceuticals has a consensus price target of $50.36, suggesting a potential upside of 94.98%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Belite Bio.
Summary
Mirum Pharmaceuticals beats Belite Bio on 12 of the 18 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
